David Steffin
@davidsteffin.bsky.social
📤 61
đź“Ą 46
đź“ť 2
Cell therapy trials for solid tumors, pediatric bone marrow transplant
Very promising news and an honor to be a part of this report!
@bcmhouston.bsky.social
@texaschildrens.bsky.social
www.nature.com/articles/s41...
loading . . .
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma - Nature Medicine
In an extended follow-up of a phase 1 trial evaluating a first-generation GD2-directed CAR-T cell therapy in patients with neuroblastoma, one patient has had a sustained clinical response for over 18 ...
https://www.nature.com/articles/s41591-025-03513-0
10 months ago
0
8
3
reposted by
David Steffin
about 1 year ago
IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
rdcu.be/d2faz
loading . . .
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Nature - We evaluate the effects in humans of interleukin-15 co-expression on glypican-3 (GPC3) chimeric antigen receptor (CAR) T cells and demonstrate that IL-15 increases the expansion,...
https://rdcu.be/d2faz
1
7
1
reposted by
David Steffin
Science News
about 1 year ago
#NatureNews
New, Effective CAR-T Strategy IL-15 increases the expansion, intratumoural survival and antitumour activity of GPC3 CAR T cells in patients.
#Medsky
#scisky
#News
#CART
#Oncology
#Cancer
1
21
7
Promising results from our phase 1 trials using GPC3-CAR T cells co-expressing IL-15 in relapsed/refractory solid tumors.
@natureportfolio.bsky.social
@bcmhouston.bsky.social
@andrasheczey.bsky.social
loading . . .
https://www.nature.com/articles/s41586-024-08261-8
https://t.co/P2fxyC2Pmk
about 1 year ago
0
4
2
you reached the end!!
feeds!
log in
